All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer

被引：0
|
作者：
Hesham Tawfik
Yousri Rostom
Hesham Elghazaly
机构：
[1] Tanta University,Clinical Oncology Department
[2] Alexandria University,Clinical Oncology Department
[3] Ain Shams University,Clinical Oncology Department
来源：
Cancer Chemotherapy and Pharmacology | 2013年 / 71卷
关键词：
Oral therapy; First-line chemotherapy; Metastatic breast cancer; HER2/Neu-negative;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：913 / 919
页数：6
相关论文
共 50 条
  • [41] A pooled analysis of efficacy and safety of vinorelbine in combination with capecitabine in first-line metastatic breast cancer (MBC)
    Valev, Spartak S.
    Taushanova, Margarita
    Krasteva, Ely
    ANNALS OF ONCOLOGY, 2007, 18 : 163 - 163
  • [42] Is the combination of trastuzumab and vinorelbine an active regimen in metastatic breast cancer patients overexpressing HER2/neu?
    Czerniawska, M
    Jagiello-Gruszfeld, AI
    Zbrzezniak, J
    Wachula, E
    Kazarnowicz, A
    Sikorska, M
    Szablowska-Siwik, S
    Ziomek, M
    Gugala, K
    ANNALS OF ONCOLOGY, 2005, 16 : 277 - 277
  • [43] A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Sunela, Kaisa
    Lehtinen, Ilari
    Joensuu, Heikki
    Sjostrom-Mattson, Johanna
    CLINICAL BREAST CANCER, 2006, 7 (05) : 401 - 405
  • [44] First-line treatment with epirubicin and vinorelbine in metastatic breast cancer
    Vici, P
    Colucci, G
    Gebbia, V
    Amodio, A
    Giotta, F
    Belli, F
    Conti, F
    Gebbia, N
    Pezzella, G
    Valerio, MR
    Brandi, M
    Pisconti, S
    Durini, E
    Giannarelli, D
    Lopez, M
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) : 2689 - 2694
  • [45] Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study
    Greil, R.
    Moik, M.
    Reitsamer, R.
    Ressler, S.
    Stoll, M.
    Namberger, K.
    Menzel, C.
    Mlineritsch, B.
    EJSO, 2009, 35 (10): : 1048 - 1054
  • [46] ALL ORAL COMBINATION OF VINORELBINE AND CAPECITABILE AS A FIRST LINE TREATMENT IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC)
    Shehata, Samir
    Khalaf, Marwa
    BREAST, 2017, 36 : S53 - S53
  • [47] Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer.
    Bayo, J
    Mayordomo, JI
    Sanchez-Rovira, P
    Perez-Carrion, R
    Illaramendi, J
    Flores, EG
    Bueno, JMG
    Vazquez, MR
    Crespo, C
    Palomo, AG
    Huelva, HJRJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 67S - 67S
  • [48] BevacizumabA Review of its Use in Combination with Paclitaxel or Capecitabine as First-Line Therapy for HER2-Negative Metastatic Breast Cancer
    Katherine F. Croom
    Sohita Dhillon
    Drugs, 2011, 71 : 2213 - 2229
  • [49] Bevacizumab A Review of its Use in Combination with Paclitaxel or Capecitabine as First-Line Therapy for HER2-Negative Metastatic Breast Cancer
    Croom, Katherine F.
    Dhillon, Sohita
    DRUGS, 2011, 71 (16) : 2213 - 2229
  • [50] Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study
    Koszo, Renata
    Santha, Dra
    Budi, Laszl
    Erfan, Jzsef
    Gyorfy, Karoly
    Horvath, Zsolt
    Kocsis, Judit
    Landherr, Laszlo
    Hitre, Erika
    Mahr, Karoly
    Pajkos, Gabor
    Papai, Zsuzsanna
    Kahan, Zsuzsanna
    PATHOLOGY & ONCOLOGY RESEARCH, 2017, 23 (03) : 505 - 511
12345